Učitavanje...
Combining immunotherapies for the treatment of prostate cancer
Sipuleucel-T, a therapeutic dendritic-cell vaccine, was Food and Drug Administration-approved for prostate cancer in 2010. No new immunotherapies for prostate cancer have been approved since. However, novel agents and combination approaches offer great promise for improving outcomes for prostate can...
Spremljeno u:
| Izdano u: | Urol Oncol |
|---|---|
| Glavni autori: | , , |
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
2017
|
| Teme: | |
| Online pristup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6599516/ https://ncbi.nlm.nih.gov/pubmed/29146441 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.urolonc.2017.09.024 |
| Oznake: |
Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!
|